Current Therapeutic Approaches to Epilepsy

Total Page:16

File Type:pdf, Size:1020Kb

Current Therapeutic Approaches to Epilepsy Review Article [Rahman et al., 4(1): Jan., 2014] CODEN (USA): IJPLCP ISSN: 0976-7126 INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES Current therapeutic approaches to epilepsy Azizur Rahman*, Fareedullah Md, Ansari Javed Akhtar and Sayyed Abdul Mateen Department of Pharmacology, MESCO College of Pharmacy, Hyderabad, (A.P.) - India Abstract Epilepsy is one of the most common ailments of man with a prevalence of approximately 1%. It is estimated that 50 millions person’s worldwide may have this disorder. Although many are well controlled with available therapies, perhaps one quarter of the total continue to have seizures. Anticonvulsant drugs are the mainstay of epilepsy management and may have to be taken for life. In more than 20% of those affected, chronic in aractable (refraction) epilepsy develops. This necessitates the use of combination therapy. But the use of these drugs in combination is plagued by cognitive impairment and drug interactions with the results that only about 10% of the patients with refractory epilepsy seem to benefit substantially from polypharmacy. The last past two decades has brought many advances to the treatment of epilepsy, including many new pharmacological agents. So substantial data has been collected both chemically as well as pharmacological point of view. Hopefully this will be helpful for Primary care physicians and as well as those involved in epilepsy patients care. Therefore they should be familiar with the new options available. Key-Words: Epilepsy, Seizures, Anticonvulsant drugs, Polypharmacy Introduction The term “epilepsy” refers to a disorder of brain The particular symptoms produced depend on the function characterized by the periodic and function of the region of the brain that is affected. Thus unpredictable occurrence of seizures. The term involvement of the hypothalamus causes peripheral “seizure” refers to a transient alteration of behaviour autonomic discharges and involvement of the reticular due to abnormal excessive, hyper synchronous formation in the upper brain stem that leads to loss of discharges from an aggregate of CNS neurons. consciousness 1. Seizure can be of following types: Aetiology a) Non epileptic - when evoked in a normal brain by Usually there is no recognizable cause (idiopathic), the treatment such as electric shock or chemical although it may be develop as a consequence of various convulsants. kinds of brain damage, such as trauma, infection or b) Epileptic - when occur without evident provocation. tumour growths 2. The epilepsies are common and frequently devastating disorder, affecting approximately 0.5 to 1% of the population. More than 40 distinct forms of epilepsy have been identified. The incidence increases again, epilepsy begins before the age of 18 in over 75% population. Seizure, the characteristic event in epilepsy is associated with the episodic high frequency discharges of impulses by a group of neurons in the brain. What starts as local abnormal discharges may then spread to other areas of the brain. The site of primary discharge and extent of its spread determines the symptoms that are produced, which range from a brief lapse of attention to a full blown convulsive fit lasting for several minutes. * Corresponding Author E.mail: [email protected], Classification of Epileptic Seizures [email protected] Epilepsy is classified in several ways: Mob.: +91 9010412319 1. Clinical events (usually seizure type). Int. J. of Pharm. & Life Sci. (IJPLS), Vol. 4, Issue 1: January: 2013, 2282-2287 2282 Review Article [Rahman et al., 4(1): Jan., 2014] CODEN (USA): IJPLCP ISSN: 0976-7126 2. Electro encephalographic changes (EEG). I II 3. Aetiology 4. Pathophsiology 5. Anatomy 6. Age The widely adopted method is the classification of seizures type in which only EEG data is taken into account. This scheme was introduced in 1969 by international league against epilepsy (ILAE) and was revised in 1981 1-3. I. Generalized II. Partial seizures 2 III. seizures 2 Unclassified epileptic III IV seizures A. Tonic– A. Simple partial clonic seizures seizures (grand mal) i) With motor B. Tonic signs seizures ii) With C. Clonic somatosensory or seizures special D. Absence sensory Fig. 1: Types of epileptic seizures. I. Normal; II. seizure hallucination Generalized tonic-clonic seizures; III. Absence (petitmal) iii) With automatic seizure; IV. Partial seizure. E. Myoclonic symptoms and seizure signs The bursting is caused by a relatively long lasting F. Atonic iv) With Psychic depolarization of the neuronal membrane due to influx seizures symptoms of extracellular calcium (Ca 2+ ), which leads to the (astatic) B. Complex partial pening of voltage dependent sodium (Na 2+ ) channel: Seizures influx of sodium and generation of repetitive action i) Simple partial potentials. This is followed by a hyperpolarizing after onset followed by potential mediated by GABA receptors of potassium impairement of channel depending on the cell type. conciousness. The synchronized bursts from a sufficient number of ii) With impaired neuro result in a so called spike discharge on the EEG. conciousness on Repetitive discharges of neurons lead to the following onset An increase in extracellular K +, C. Partial seizures which blunts the activity of hyperpolarization evolving to and depolarizes neighbouring neurons. secondary Accumulation of Ca 2+ in presynaptic generalized terminals, leading to enhance neurotransmitter seizures. release. Basic mechanisms of seizures initiation and Depolarization induced activation of propagation the NMDA subtype of the excitatory amino Partial seizure activity can begin in a very discrete acid receptor, which causes more Ca 2+ influx region of cortex and then spread to neighbouring and neuronal activation. regions i.e., there is a seizure initiation phase and a The recruitment of a sufficient number of neurons seizure propagation phase. Studies of experimental leads to a loss of the surrounding inhibition and models of these phases suggest that the initiation phase propagation of seizure activity into contiguous areas is characterized by two concurrent events in aggregate via local cortical connection and to more distant areas neurons. via long commissural pathways such as the corpus 1. High frequency burst of action potential and callosum. 2. Hypersynchronization Int. J. of Pharm. & Life Sci. (IJPLS), Vol. 4, Issue 1: January: 2013, 2282-2287 2283 Review Article [Rahman et al., 4(1): Jan., 2014] CODEN (USA): IJPLCP ISSN: 0976-7126 Epileptogenesis 4. OXAZOLIDINEDIONES clonic Seizures Epileptogenesis refers to the transformation of normal • Trimethadione Generalised Tonic- neurons network into one that is chronically • Paramethadion clonic Seizures hyperexcitable. For example, there is often a delay of e month to year between an initial injury such as trauma, 5. SUCCINIMIDES Generalised Tonic- stroke or infection and the first seizure. The injury • Ethosuximide clonic Seizures appears to initiate a process that gradually lowers the • Phensuximide Generalised Tonic- seizure threshold in the effected region until a 6. ALIPHATIC CARBOXYLIC clonic Seizures spontaneous seizure occurs. Pathologic studies of the ACID hippocampus from patients with temporal lobe epilepsy • Valproic Acid Generalised Tonic- (MTLE) are related to structural change in neuronal • Divalproex clonic Seizures networks. For example many patients with MTLE 7. BENZODIAZEPINES Generalised Tonic- syndrome have a highly selective loss of neurons clonic Seizures • Clonazepam within the dentate gyrus. In response, to the loss of • Diazepam neurons, there is recognition or “spouting” of surviving Absence Seizures • Lorazepam neurons in a way that affects the excitability of the Absence Seizures 8. NEWER DRUGS network. Thus an initial injury such as head injury may • lead to a very focal, confined region of structural Lamotrigine Partial and • change that causes local hyperexcitability. Gabapentin generalised tonic • The local hyperexcitability leads to further structure Levetiracetam clonic, absence change that evolves over time unit the focal lesion • Tiagabine seizure produces clinically evident seizures. • Felbamate Absence seizure Genetic cause of epilepsy • Topiramate The genetic causes of a few epilepsy syndromes have • Zonisamide Absence Seizures recently been discovered. They are: • Viagabatrin Status Epilepticus Myoclonic epilepsy with ragged red Absence fibres (MERRF) syndrome is associated with seizures,Myocloni a mutation of mitochondrial lysine. c Seizures Mutation in the cystation B give may cause another form of progressive myoclonus epilepsy. adjuvant in partial Mutation with gene encoding the B4 and secondarily subunit of the acetyl choline receptor appears generalised responsible for a frontal lobe epilepsy seizures syndrome. adjuvant in partial Treatment of epilepsy and secondarily Antiepileptics are agents used medically to control the generalised epilepsy; these are the mainstay of epilepsy seizures management. Refractory Partial Classification 3,6,7,8 Epilepsy Drugs Types of seizures Partial and Used Generalised Tonic 1. BARBITURATES Clonic Seizure • Phenobarbital Generalised tonic- Lennox Gastaut • Mephobarbital clonic seizures Syndrome • Primidone Generalised tonic- Refractory Partial 2. HYDANTOINS clonic seizures Epilepsy, Lennox • Phenytoin Generalised tonic- Gastaut Syndrome • Mephytoin clonic seizure Refractory Partial • Ethotoin Epilepsy 3. IMINOSTILBENES Complex partial Partial Epilepsy seizure • Carbamazepine Generalised Tonic- • Oxcarbazepine Int. J.
Recommended publications
  • Therapeutic Class Brand Name P a Status Generic
    P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE
    [Show full text]
  • In Silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction
    In silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction Pathima Nusrath Hameed ORCID: 0000-0002-8118-9823 Submitted in total fulfilment of the requirements for the degree of Doctor of Philosophy Department of Mechanical Engineering THE UNIVERSITY OF MELBOURNE May 2018 Copyright © 2018 Pathima Nusrath Hameed All rights reserved. No part of the publication may be reproduced in any form by print, photoprint, microfilm or any other means without written permission from the author. Abstract Drug repositioning and drug-drug interaction (DDI) prediction are two fundamental ap- plications having a large impact on drug development and clinical care. Drug reposi- tioning aims to identify new uses for existing drugs. Moreover, understanding harmful DDIs is essential to enhance the effects of clinical care. Exploring both therapeutic uses and adverse effects of drugs or a pair of drugs have significant benefits in pharmacology. The use of computational methods to support drug repositioning and DDI prediction en- able improvements in the speed of drug development compared to in vivo and in vitro methods. This thesis investigates the consequences of employing a representative training sam- ple in achieving better performance for DDI classification. The Positive-Unlabeled Learn- ing method introduced in this thesis aims to employ representative positives as well as reliable negatives to train the binary classifier for inferring potential DDIs. Moreover, it explores the importance of a finer-grained similarity metric to represent the pairwise drug similarities. Drug repositioning can be approached by new indication detection. In this study, Anatomical Therapeutic Chemical (ATC) classification is used as the primary source to determine the indications/therapeutic uses of drugs for drug repositioning.
    [Show full text]
  • Therapeutic Class Overview Anticonvulsants
    Therapeutic Class Overview Anticonvulsants INTRODUCTION Epilepsy is a disease of the brain defined by any of the following (Fisher et al 2014): ○ At least 2 unprovoked (or reflex) seizures occurring > 24 hours apart; ○ 1 unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after 2 unprovoked seizures, occurring over the next 10 years; ○ Diagnosis of an epilepsy syndrome. Types of seizures include generalized seizures, focal (partial) seizures, and status epilepticus (Centers for Disease Control and Prevention [CDC] 2018, Epilepsy Foundation 2016). ○ Generalized seizures affect both sides of the brain and include: . Tonic-clonic (grand mal): begin with stiffening of the limbs, followed by jerking of the limbs and face . Myoclonic: characterized by rapid, brief contractions of body muscles, usually on both sides of the body at the same time . Atonic: characterized by abrupt loss of muscle tone; they are also called drop attacks or akinetic seizures and can result in injury due to falls . Absence (petit mal): characterized by brief lapses of awareness, sometimes with staring, that begin and end abruptly; they are more common in children than adults and may be accompanied by brief myoclonic jerking of the eyelids or facial muscles, a loss of muscle tone, or automatisms. ○ Focal seizures are located in just 1 area of the brain and include: . Simple: affect a small part of the brain; can affect movement, sensations, and emotion, without a loss of consciousness . Complex: affect a larger area of the brain than simple focal seizures and the patient loses awareness; episodes typically begin with a blank stare, followed by chewing movements, picking at or fumbling with clothing, mumbling, and performing repeated unorganized movements or wandering; they may also be called “temporal lobe epilepsy” or “psychomotor epilepsy” .
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]
  • Clinical Review, Adverse Events
    Clinical Review, Adverse Events Drug: Carbamazepine NDA: 16-608, Tegretol 20-712, Carbatrol 21-710, Equetro Adverse Event: Stevens-Johnson Syndrome Reviewer: Ronald Farkas, MD, PhD Medical Reviewer, DNP, ODE I 1. Executive Summary 1.1 Background Carbamazepine (CBZ) is an anticonvulsant with FDA-approved indications in epilepsy, bipolar disorder and neuropathic pain. CBZ is associated with Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), closely related serious cutaneous adverse drug reactions that can be permanently disabling or fatal. Other anticonvulsants, including phenytoin, phenobarbital, and lamotrigine are also associated with SJS/TEN, as are members of a variety of other drug classes, including nonsteriodal anti-inflammatory drugs and sulfa drugs. The incidence of CBZ-associated SJS/TEN has been considered “extremely rare,” as noted in current U.S. drug labeling. However, recent publications and postmarketing data suggest that CBZ- associated SJS/TEN occurs at a much higher rate in some Asian populations, about 2.5 cases per 1,000 new exposures, and that most of this increased risk is in individuals carrying a specific human leukocyte antigen (HLA) allele, HLA-B*1502. This HLA-B allele is present in about 5- to 20% of many, but not all, Asian populations, and is also present in about 2- to 4% of South Asians/Indians. The allele is also present at a lower frequency, < 1%, in several other ethnic groups around the world (although likely due to distant Asian ancestry). About 10% of U.S. Asians carry HLA-B*1502. HLA-B*1502 is generally not present in the U.S.
    [Show full text]
  • Tegretol (Carbamazepine)
    Page 3 Tegretol® carbamazepine USP Chewable Tablets of 100 mg - red-speckled, pink Tablets of 200 mg – pink Suspension of 100 mg/5 mL Tegretol®-XR (carbamazepine extended-release tablets) 100 mg, 200 mg, 400 mg Rx only Prescribing Information WARNING SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH TEGRETOL. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT- RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH TEGRETOL. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH TEGRETOL UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK (SEE WARNINGS AND PRECAUTIONS/LABORATORY TESTS). APLASTIC ANEMIA AND AGRANULOCYTOSIS APLASTIC ANEMIA AND AGRANULOCYTOSIS HAVE BEEN REPORTED IN ASSOCIATION WITH THE USE OF TEGRETOL. DATA FROM A POPULATION-BASED CASE CONTROL STUDY DEMONSTRATE THAT THE RISK OF DEVELOPING THESE REACTIONS IS 5-8 TIMES GREATER THAN IN THE GENERAL POPULATION. HOWEVER, THE OVERALL RISK OF THESE REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW, APPROXIMATELY SIX PATIENTS PER ONE MILLION POPULATION PER YEAR FOR AGRANULOCYTOSIS AND TWO PATIENTS PER ONE MILLION POPULATION PER YEAR FOR APLASTIC ANEMIA.
    [Show full text]
  • Non-Opioid Analgesic Definition Regional Any Charge Code Or Professional Fee Associated with Epidural Catheter Placement, Periph
    Table S1: Definition of non-opioid analgesics Non-Opioid Analgesic Definition Regional Any charge code or professional fee associated with epidural catheter placement, peripheral nerve block placement or peripheral nerve catheter placement Acetaminophen Any charge for acetaminophen either as a sole agent or in combination with another medication Non-Selective NSAIDs Any code listing choline salicylate, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketorketoprofen, ketorolac, meclofenamate, meloxicam , nabumetone, naproxen, oxaprozin , piroxicam , salsalate, sulindac, tolmetin COX-2 Inhibitors Any code listing celecoxib, rofecoxib, valdecoxib Gabapentinoids Any code listing gabapentin, pregabalin Ketamine Any code listing ketamine Table S2: List of ICD-9 codes used to generate covariates Covariate ICD-9 Codes History of Substance Use/Abuse Alcohol abuse 265.2, 291.1–291.3, 291.5–291.9, 303.0, 303.9, 305.0, 357.5, 425.5, 535.3, 571.0–571.3, 980.xx, V11.3 Drug Abuse 292.xx, 304.xx, 305.2–305.9, V65.42 Tobacco Use* 305.1x; V15.82, 649.0x Pain Conditions:* Back Pain 720.xx - 724.xx, 738.4x, 739.3x, 739.4x, 756.11, 756.12, 805.xx, 846.xx, 847.xx, 648.7x Fibromyalgia and or pain 729.1 Migraine or other headache syndrome 346.xx, 339.0x-339.8x; 784.0x Chronic Pain 338.0x (338.1x excluded), 338.2x, 338.4x Rheumatoid Arthritis 714.xx Solid tumor without metastasis 140.xx–172.xx, 174.xx–195.xx Metastatic cancer 196.xx–199.xx Lymphoma 200.xx–202.xx, 203.0, 238.6 Psychiatric Comorbidities Anxiety 300.0x, 300.2x,
    [Show full text]
  • Phenytoin Assay Azide, Preservatives, and Stabilizers
    4 REAgENtS Reagents contain the following substances: Mouse monoclonal antibodies reactive to phenytoin (53.4 µg/mL), glucose-6-phosphate (22 mM), nicotinamide adenine dinucleotide (18 mM), phenytoin labeled with glucose-6-phosphate dehydrogenase (0.24 U/mL), Tris buffer, 0.1% sodium Phenytoin Assay azide, preservatives, and stabilizers. Precautions • For in vitro diagnostic use. September 2010 4A152.2D_B • Contains nonsterile mouse monoclonal antibodies. • Assay components contain sodium azide, which may react with lead and copper plumbing See shaded sections: to form highly explosive metal azides. If waste is discarded down the drain, flush it with a Updated information from March 2008 edition. large volume of water to prevent azide buildup. • Do not use the kit after the expiration date. • This kit contains streptomycin sulfate. Please dispose of appropriately. • Turbid or yellow reagents may indicate contamination or degradation and must be discarded. Preparation of Reagents Catalog Quantity/ The Emit® 2000 Phenytoin Assay reagents are provided ready to use; no preparation is Number Product Description Volume necessary. OSR4A229 Emit® 2000 Phenytoin Assay Storage of Assay Components OSR4A518 R1 (Antibody/Substrate Reagent 1) 2 x 21 mL • Improper storage of reagents can affect assay performance. OSR4A548 R2 (Enzyme Reagent 2) 2 x 16 mL • When not in use, store reagents upright at 2–8°C and with screw caps tightly closed. † • Unopened reagents are stable until the expiration date printed on the label if stored upright at 4A109UL Emit® 2000 Phenytoin Calibrators* 1 x 5 mL , 2–8°C. 5 x 2 mL • Do not freeze reagents or expose them to temperatures above 32°C.
    [Show full text]
  • Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With
    University of Rhode Island DigitalCommons@URI Pharmacy Practice Faculty Publications Pharmacy Practice 2018 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Antiepileptic Drugs: An Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Eric P. Borrelli University of Rhode Island, [email protected] Erica Y. Lee University of Rhode Island SeFoe nelloxtw pa thige fors aaddndition addal aitutionhorsal works at: https://digitalcommons.uri.edu/php_facpubs The University of Rhode Island Faculty have made this article openly available. Please let us know how Open Access to this research benefits oy u. This is a pre-publication author manuscript of the final, published article. Terms of Use This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our Terms of Use. Citation/Publisher Attribution Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens‐Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018;00:1–7. https://doi.org/10.1111/epi.14591 Available at: https://doi.org/10.1111/epi.14591 This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. Authors Eric P. Borrelli, Erica Y. Lee, Andrew M. Descoteaux, Stephen Jon Kogut, and Aisling R. Caffrey This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/php_facpubs/124 Title: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Antiepileptic Drugs: An Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Authors: Eric P.
    [Show full text]
  • "2-Oxo-1-Pyrrolidine Derivative and Its Pharmaceutical Uses"
    (19) & (11) EP 1 452 524 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 207/27 (2006.01) A61K 31/4015 (2006.01) 14.10.2009 Bulletin 2009/42 A61P 25/08 (2006.01) (21) Application number: 04007878.4 (22) Date of filing: 21.02.2001 (54) "2-oxo-1-pyrrolidine derivative and its pharmaceutical uses" "2-Oxo-1-Pyrrolidinderivate und ihre pharmazeutische Verwendung" "Dérivé de 2-oxo-1-pyrrolidine et ses applications pharmaceutique" (84) Designated Contracting States: • Talaga, Patrice AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 1170 Watermael-Boitsfort (BE) MC NL PT SE TR (74) Representative: UCB (30) Priority: 23.02.2000 GB 0004297 Intellectual Property c/o UCB S.A. (43) Date of publication of application: Intellectual Property Department 01.09.2004 Bulletin 2004/36 Allée de la Recherche 60 1070 Brussels (BE) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (56) References cited: 01925354.1 / 1 265 862 WO-A-99/13911 GB-A- 1 309 692 (73) Proprietor: UCB Pharma, S.A. • PROUS: "LEVETIRACETAM" DRUGS OF THE 1170 Brussels (BE) FUTURE, BARCELONA, ES, vol. 19, no. 2, 1994, pages 111-113, XP000908882 ISSN: 0377-8282 (72) Inventors: • FISCHER W ET AL: "Die Wirksamkeit von • Differding, Edmond Piracetam, Meclofenoxat und Vinpocetin in 1348 Ottignies-Louvain-La-Neuve (BE) verschiedenen Krampfmodellen bei der Maus" • Kenda, Benoît PHARMAZIE, VEB VERLAG VOLK UND 5080 Emines (BE) GESUNDHEIT. BERLIN, DD, vol. 46, no.
    [Show full text]